MX2015017124A - Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer. - Google Patents
Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.Info
- Publication number
- MX2015017124A MX2015017124A MX2015017124A MX2015017124A MX2015017124A MX 2015017124 A MX2015017124 A MX 2015017124A MX 2015017124 A MX2015017124 A MX 2015017124A MX 2015017124 A MX2015017124 A MX 2015017124A MX 2015017124 A MX2015017124 A MX 2015017124A
- Authority
- MX
- Mexico
- Prior art keywords
- capecitabine
- component
- effective amount
- products
- therapeutically effective
- Prior art date
Links
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title abstract 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004117 capecitabine Drugs 0.000 title abstract 2
- 238000011275 oncology therapy Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 1
- 229960001756 oxaliplatin Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dermatology (AREA)
Abstract
La presente solicitud describe productos farmacéuticos que comprenden a) como un primer componente, una composición farmacéutica que comprende como un ingrediente activo, una cantidad terapéuticamente efectiva del compuesto de fórmula (ver Fórmula) o una sal, éster o profármaco farmacéuticamente aceptable del compuesto; b) un segundo componente que comprende una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de capecitabina; y c) un tercer componente que comprende una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de oxaliplatino. La solicitud también describe métodos para el tratamiento del cáncer utilizando los productos, así como equipos que contienen los productos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361836899P | 2013-06-19 | 2013-06-19 | |
| PCT/EP2014/062496 WO2014202497A1 (en) | 2013-06-19 | 2014-06-16 | Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015017124A true MX2015017124A (es) | 2016-03-07 |
Family
ID=50976625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017124A MX2015017124A (es) | 2013-06-19 | 2014-06-16 | Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160129034A1 (es) |
| EP (1) | EP3010508B1 (es) |
| JP (1) | JP6549107B2 (es) |
| KR (1) | KR20160009677A (es) |
| CN (1) | CN105263499B (es) |
| BR (1) | BR112015030734A2 (es) |
| CA (1) | CA2912743A1 (es) |
| ES (1) | ES2747073T3 (es) |
| MX (1) | MX2015017124A (es) |
| PL (1) | PL3010508T3 (es) |
| RU (1) | RU2015152175A (es) |
| WO (1) | WO2014202497A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021033144A1 (en) * | 2019-08-20 | 2021-02-25 | Intas Pharmaceuticals Ltd. | Oral suspension of capecitabine |
| CN113698435B (zh) * | 2021-08-25 | 2023-09-29 | 中国人民解放军空军军医大学 | 一类含有p53-MDM2抑制剂的四价铂配合物及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8232298B2 (en) * | 2006-03-22 | 2012-07-31 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between MDM2 and P53 |
| KR101434009B1 (ko) * | 2008-08-04 | 2014-08-25 | 와이어쓰 엘엘씨 | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
-
2014
- 2014-06-16 BR BR112015030734A patent/BR112015030734A2/pt not_active IP Right Cessation
- 2014-06-16 MX MX2015017124A patent/MX2015017124A/es unknown
- 2014-06-16 JP JP2016520399A patent/JP6549107B2/ja not_active Expired - Fee Related
- 2014-06-16 CA CA2912743A patent/CA2912743A1/en not_active Abandoned
- 2014-06-16 PL PL14731223T patent/PL3010508T3/pl unknown
- 2014-06-16 KR KR1020157035737A patent/KR20160009677A/ko not_active Ceased
- 2014-06-16 RU RU2015152175A patent/RU2015152175A/ru not_active Application Discontinuation
- 2014-06-16 CN CN201480032428.2A patent/CN105263499B/zh not_active Expired - Fee Related
- 2014-06-16 ES ES14731223T patent/ES2747073T3/es active Active
- 2014-06-16 WO PCT/EP2014/062496 patent/WO2014202497A1/en not_active Ceased
- 2014-06-16 US US14/897,416 patent/US20160129034A1/en not_active Abandoned
- 2014-06-16 EP EP14731223.5A patent/EP3010508B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3010508T3 (pl) | 2019-12-31 |
| EP3010508A1 (en) | 2016-04-27 |
| EP3010508B1 (en) | 2019-07-24 |
| RU2015152175A (ru) | 2017-07-24 |
| KR20160009677A (ko) | 2016-01-26 |
| WO2014202497A1 (en) | 2014-12-24 |
| ES2747073T3 (es) | 2020-03-10 |
| JP2016521760A (ja) | 2016-07-25 |
| BR112015030734A2 (pt) | 2017-07-25 |
| CA2912743A1 (en) | 2014-12-24 |
| CN105263499B (zh) | 2019-11-15 |
| HK1213475A1 (zh) | 2016-07-08 |
| US20160129034A1 (en) | 2016-05-12 |
| JP6549107B2 (ja) | 2019-07-24 |
| RU2015152175A3 (es) | 2018-04-02 |
| CN105263499A (zh) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202308496B (en) | Pharmaceutical compositions of therapeutically active compounds | |
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| GEAP201914678A (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| WO2015070224A3 (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2015017964A (es) | Inhibidores de bromodominio. | |
| MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| PH12016500164A1 (en) | Therapeutically active compounds and their methods of use | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
| PH12016501788B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. | |
| MX2015017124A (es) | Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer. | |
| WO2016112304A8 (en) | Furoquinolinediones as inhibitors of tdp2 |